20949-84-2

Basic information

• Product Name: 4-FORMYL-2-METHYLTHIAZOLE
• Synonyms: IFLAB-BB F2124-0689;4-FORMYL-2-METHYLTHIAZOLE;4-THIAZOLECARBOXALDEHYDE, 2-METHYL-;2-METHYL-1,3-THIAZOLE-4-CARBALDEHYDE;2-Methyl-1,3-thiazole-4-carboxaldehyde;2-Methyl-1,3-thiazole-4-carboxaldehyde 97%;4-Formyl-2-methyl-1,3-thiazole;2-Methyl-4-thiazolecarboxaldehyde
• CAS NO: 20949-84-2
• Molecular Formula: C₅H₅NOS
• Molecular Weight: 127.16
• EINECS: 1533716-785-6
• Product Categories: Building Blocks;Thiazole
• Mol File: 20949-84-2.mol

Chemical Properties

• Melting Point: 56-58
• Boiling Point: 219 °C at 760 mmHg
• Flash Point: 110℃
• Appearance: /
• Density: 1.27 g/cm³
• Vapor Pressure: 0.122mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.22±0.10(Predicted)
• CAS DataBase Reference: 4-FORMYL-2-METHYLTHIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FORMYL-2-METHYLTHIAZOLE(20949-84-2)
• EPA Substance Registry System: 4-FORMYL-2-METHYLTHIAZOLE(20949-84-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 20949-84-2(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Powder

InChI:InChI=1/C5H5NOS/c1-4-6-5(2-7)3-8-4/h2-3H,1H3

Upstream product

• 20949-79-5 4-dibromomethyl-2-methyl-thiazole 
• 6436-59-5 ethyl 2-methylthiazole-4-carboxylate 
• 77470-53-2 4-chloromethyl-2-methylthiazole hydrochloride 
• 39238-07-8 4-(chloromethyl)-2-methyl-1,3-thiazole 
• 76632-23-0 4-(hydroxymethyl)-2-methylthiazole 
• 79-37-8 oxalyl dichloride 
• 67-68-5 dimethyl sulfoxide 
• 108-18-9 diisopropylamine 
• 6436-60-8 methyl 2-methyl-1,3-thiazole-4-carboxylate 
• 22584-59-4 4-dibromomethyl-2-methyl-4,5-dihydro-thiazol-4-ol; hydrobromide 
• 721455-02-3 N-methoxy-N,2-dimethylthiazole-4-carboxamide 

Downstream Products

• 23002-78-0 4-acetyl-2-methylthiazole 
• 80378-02-5 1-(2-Hydroxyphenyl)-3-(2-methyl-4-thiazolyl)propenone 
• 107263-89-8 (2-Methyl-4-thiazolyl)acetylene 
• 193146-53-1 (5S,8R,9S,10S,17S,Z)-9-(tert-butyldimethylsilyloxy)-5-(2-hydroxyethyl)-2,2,3,3,6,6,8,10,14,19,19,20,20-tridecamethyl-17-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,18-dioxa-3,19-disilahenicos-14-en-7-one 
• 193146-51-9 (7S,10R,11S,12S,19S,Z)-7,11-bis(tert-butyldimethylsilyloxy)-2,2,3,3,8,8,10,12,16,21,21,22,22-tridecamethyl-19-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,20-dioxa-3,21-disilatricos-16-en-9-one 
• 193146-49-5 (7S,10R,11S,12S,19S,Z)-7-(tert-butyldimethylsilyloxy)-11-hydroxy-2,2,3,3,8,8,10,12,16,21,21,22,22-tridecamethyl-19-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,20-dioxa-3,21-disilatricos-16-en-9-one 
• 193146-63-3 (12Z,16E)-(3S,6R,7S,8S,15S)-3,7,15-tris-(tert-butyl-dimethyl-silanyloxy)-4,4,6,8,12,16-hexamethyl-17-(2-methyl-thiazol-4-yl)-5-oxo-heptadeca-12,16-dienoic acid 
• 193146-26-8 (3S,6R,7S,8S,12Z,15S,16E)-3,7-bis{[tert-butyl(dimethyl)silyl]oxy}-15-hydroxy-4,4,6,8,12,16-hexamethyl-17-(2-methyl-1,3-thiazol-4-yl)-5-oxoheptadeca-12,16-dienoic acid 
• 212850-72-1 3-(2-chloro-phenyl)-6-fluoro-2-[2-(2-methyl-thiazol-4-yl)-vinyl]-3H-quinazolin-4-one 
• 153027-88-4 1-(2-methylthiazol-4-yl)prop-2-yn-1-ol 
• 686267-28-7 4-benzyl-6-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-7-hydroxy[1,3]thiazolo[4,5-b]pyridin-5(4H)-one 
• 1187020-67-2 4-(2-methylthiazol-4-yl)-2,6-dimethyl-3,5-dibenzoyl-1,4-dihydropyridine 
• 1184867-79-5 C₃₆H₃₉N₅O₅S 
• 1007877-11-3 (S)-tert-butyl 1-((benzofuran-5-ylmethyl)((2-methylthiazol-4-yl)methyl)amino)-1-oxo-3-phenylpropan-2-ylcarbamate 

Relevant articles and documents

Synthesis and S(RN)1 reactions in 5-nitrothiazole series

A new heterocyclic reductive alkylating agent, the 2-methyl-4-chloromethyl-5-nitrothiazole, has been synthesized and could react with the 2-nitropropane anion as nucleophile, to give the 2-methyl-4-(2-methylpropenyl)-5-nitrothiazole as the major product.

An efficient total synthesis of (-)-epothilone B

An efficient total synthesis of (-)-epothilone B has been achieved in ca. 8% yield over 11 steps from 9 (or 10 steps from 7/8), which features a bissiloxane-tethered ring closing metathesis reaction to approach the trisubstituted (Z) double bond and forms a new basis for further development of an industrial process for epothilone B and ixabepilone.

Synthesis of new 1,4-dihydropyridine derivatives containing thiazolyl substituents

A series of 4-[2-methyl (or aryl) thiazole-4-yl]-2,6-dimethyl-3,5-diacetyl (or dibenzoyl) 1,4-dihydropyridines were synthesized using a modified Hantzsch reaction involving the condensation of the corresponding aldehyde with acetyl acetone or benzoyl acetone. The preparation of the corresponding aldehydes (2-methylthiazole-4-carboxaldehyde and some 2-arylthiazole-4-carboxaldehydes) was achieved by a simplified protocol of the published synthesis.

Total synthesis of epothilones B and D: Stannane equivalents for β-keto ester dianions

(Chemical Equation Presented) Studies leading to a total synthesis of epothilones B and D are described. The overall synthetic plan was based on late-stage fragment assembly of two segments representing C1-C 9 and C10-C21 of the structure. The C 1-C9 fragment was prepared by elaboration of commercially available (2R)-3-hydroxy-2-methylpropanoate at both ends of the three-carbon unit. Introduction of carbons 1-4 containing the gem-dimethyl unit was achieved in a convergent manner using a diastereoselective addition of a stannane equivalent of a β-keto ester dianion. An enantioselective addition of such a stannane equivalent for a β-keto ester dianion was also used to fashion one version of the C10-C21 subunit; however, the fragment assembly (using bimolecular esterification followed by ring-closing metathesis) with this subunit failed. Therefore, fragment assembly was achieved using a Wittig reaction; this was followed by macrolactonization to close the macrocycle. The C10-C21 subunit needed for this approach was prepared in an efficient manner using the Corey-Kim reaction as a key element. Other key reactions in the synthesis include a stereoselective SmI 2 reduction of a β-hydroxy ketone and a critical opening of a valerolactone with aniline which required extensive investigation.

Design and synthesis C6-C8 bridged epothilone a

A conformationally restrained epothilone A analogue (3) with a short bridge between methyl groups at C6 and C8 was designed and synthesized. Preliminary biological evaluation indicates 3 to be only weakly active (IC50 = 8.5 μM) against the A2780 human ovarian cancer cell line.

Epothilon derivatives, method for the production and the use thereof as pharmaceuticals

Disclosed are epothilone compounds of formula I, which are useful as pharmaceutical compounds for treating, for example, malignant tumors and chronic inflammatory diseases and are useful in anti-angiogenesis therapy.

Pyrazolopyrimidines as therapeutic agents

The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Design, synthesis and biological evaluation of novel, simplified analogues of laulimalide: Modification of the side chain

Novel, simplified analogues of the microtubule-stabilizing anticancer agent laulimalide, including the first derivatives with unnatural side chains, were designed by molecular modelling, synthesized by a late-stage diversification strategy, and evaluated in vitro for growth inhibition of human ovarian carcinoma cell lines (A2780, A2780/AD10).

4-[(4-(CARBOXYETHYL) PIPERIDINYL) METHYL] PYRROLIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

3-Substituted pyrrolidines having a 4-carboxypiperidinylmethyl substituent on the 4-position of the ring are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.